Keeping an eye on $BRKR after a sharp two-session pullback with no clear new company-specific setback. Core instrument bookings grew 10% organically, margins improved and 2026 EPS guidance held; soft U.S. academic demand, modest organic growth and the large prior rally remain the key risks. There may still be details the market is pricing in that I haven't caught yet;this is a watch, not a verdict.
112 views
0 Comments
No comments available.
Join the conversation with 500,000+ other investors 💸
Create an account to get access to everything Blossom has to offer!
📊 Personalized algorithm based on your investing style, experience level and interests
📈 Powerful portfolio and dividend tracking tools
👀 See what top creators and others in the community are investing in
